These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

514 related items for PubMed ID: 23526814

  • 21. Design, synthesis, and biological activity of NCC149 derivatives as histone deacetylase 8-selective inhibitors.
    Suzuki T, Muto N, Bando M, Itoh Y, Masaki A, Ri M, Ota Y, Nakagawa H, Iida S, Shirahige K, Miyata N.
    ChemMedChem; 2014 Mar; 9(3):657-64. PubMed ID: 24403121
    [Abstract] [Full Text] [Related]

  • 22. Identification of novel, selective, and stable inhibitors of class II histone deacetylases. Validation studies of the inhibition of the enzymatic activity of HDAC4 by small molecules as a novel approach for cancer therapy.
    Ontoria JM, Altamura S, Di Marco A, Ferrigno F, Laufer R, Muraglia E, Palumbi MC, Rowley M, Scarpelli R, Schultz-Fademrecht C, Serafini S, Steinkühler C, Jones P.
    J Med Chem; 2009 Nov 12; 52(21):6782-9. PubMed ID: 19888759
    [Abstract] [Full Text] [Related]

  • 23. Synthesis and biological characterization of spiro[2H-(1,3)-benzoxazine-2,4'-piperidine] based histone deacetylase inhibitors.
    Thaler F, Varasi M, Abate A, Carenzi G, Colombo A, Bigogno C, Boggio R, Zuffo RD, Rapetti D, Resconi A, Regalia N, Vultaggio S, Dondio G, Gagliardi S, Minucci S, Mercurio C.
    Eur J Med Chem; 2013 Jun 12; 64():273-84. PubMed ID: 23644210
    [Abstract] [Full Text] [Related]

  • 24. Discovery of potent HDAC inhibitors based on chlamydocin with inhibitory effects on cell migration.
    Wang S, Li X, Wei Y, Xiu Z, Nishino N.
    ChemMedChem; 2014 Mar 12; 9(3):627-37. PubMed ID: 24285590
    [Abstract] [Full Text] [Related]

  • 25. Novel N-hydroxyfurylacrylamide-based histone deacetylase (HDAC) inhibitors with branched CAP group (Part 2).
    Feng T, Wang H, Su H, Lu H, Yu L, Zhang X, Sun H, You Q.
    Bioorg Med Chem; 2013 Sep 01; 21(17):5339-54. PubMed ID: 23820574
    [Abstract] [Full Text] [Related]

  • 26. Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitors.
    Jiang BE, Hu J, Liu H, Liu Z, Wen Y, Liu M, Zhang HK, Pang X, Yu LF.
    Eur J Med Chem; 2022 Jan 05; 227():113893. PubMed ID: 34656899
    [Abstract] [Full Text] [Related]

  • 27. Pyrimidinedione-mediated selective histone deacetylase 6 inhibitors with antitumor activity in colorectal cancer HCT116 cells.
    Liu YM, Lee HY, Lai MJ, Pan SL, Huang HL, Kuo FC, Chen MC, Liou JP.
    Org Biomol Chem; 2015 Oct 28; 13(40):10226-35. PubMed ID: 26309122
    [Abstract] [Full Text] [Related]

  • 28. Design, synthesis and docking studies on benzamide derivatives as histone deacetylase inhibitors.
    Lu A, Luo H, Shi M, Wu G, Yuan Y, Liu J, Tang F.
    Bioorg Med Chem Lett; 2011 Aug 15; 21(16):4924-7. PubMed ID: 21741834
    [Abstract] [Full Text] [Related]

  • 29. Novel spiroindoline HDAC inhibitors: Synthesis, molecular modelling and biological studies.
    Brindisi M, Senger J, Cavella C, Grillo A, Chemi G, Gemma S, Cucinella DM, Lamponi S, Sarno F, Iside C, Nebbioso A, Novellino E, Shaik TB, Romier C, Herp D, Jung M, Butini S, Campiani G, Altucci L, Brogi S.
    Eur J Med Chem; 2018 Sep 05; 157():127-138. PubMed ID: 30092367
    [Abstract] [Full Text] [Related]

  • 30. Synthesis and biological properties of novel, uracil-containing histone deacetylase inhibitors.
    Mai A, Massa S, Rotili D, Simeoni S, Ragno R, Botta G, Nebbioso A, Miceli M, Altucci L, Brosch G.
    J Med Chem; 2006 Oct 05; 49(20):6046-56. PubMed ID: 17004718
    [Abstract] [Full Text] [Related]

  • 31. Synthesis and biological characterization of the histone deacetylase inhibitor largazole and C7- modified analogues.
    Souto JA, Vaz E, Lepore I, Pöppler AC, Franci G, Alvarez R, Altucci L, de Lera AR.
    J Med Chem; 2010 Jun 24; 53(12):4654-67. PubMed ID: 20491440
    [Abstract] [Full Text] [Related]

  • 32. Development of 3-hydroxycinnamamide-based HDAC inhibitors with potent in vitro and in vivo anti-tumor activity.
    Li X, Hou J, Li X, Jiang Y, Liu X, Mu W, Jin Y, Zhang Y, Xu W.
    Eur J Med Chem; 2015 Jan 07; 89():628-37. PubMed ID: 25462271
    [Abstract] [Full Text] [Related]

  • 33. Synthesis of 1,2-benzisoxazole tethered 1,2,3-triazoles that exhibit anticancer activity in acute myeloid leukemia cell lines by inhibiting histone deacetylases, and inducing p21 and tubulin acetylation.
    Ashwini N, Garg M, Mohan CD, Fuchs JE, Rangappa S, Anusha S, Swaroop TR, Rakesh KS, Kanojia D, Madan V, Bender A, Koeffler HP, Basappa, Rangappa KS.
    Bioorg Med Chem; 2015 Sep 15; 23(18):6157-65. PubMed ID: 26299825
    [Abstract] [Full Text] [Related]

  • 34. Modified cap group suberoylanilide hydroxamic acid histone deacetylase inhibitor derivatives reveal improved selective antileukemic activity.
    Salmi-Smail C, Fabre A, Dequiedt F, Restouin A, Castellano R, Garbit S, Roche P, Morelli X, Brunel JM, Collette Y.
    J Med Chem; 2010 Apr 22; 53(8):3038-47. PubMed ID: 20218673
    [Abstract] [Full Text] [Related]

  • 35. Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
    Cheng C, Yun F, He J, Ullah S, Yuan Q.
    Eur J Med Chem; 2019 Jul 01; 173():185-202. PubMed ID: 31003060
    [Abstract] [Full Text] [Related]

  • 36. Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation.
    Park JH, Jung Y, Kim TY, Kim SG, Jong HS, Lee JW, Kim DK, Lee JS, Kim NK, Kim TY, Bang YJ.
    Clin Cancer Res; 2004 Aug 01; 10(15):5271-81. PubMed ID: 15297431
    [Abstract] [Full Text] [Related]

  • 37. Design, synthesis and biological evaluation of indeno[1,2-d]thiazole derivatives as potent histone deacetylase inhibitors.
    Zhou M, Ning C, Liu R, He Y, Yu N.
    Bioorg Med Chem Lett; 2013 Jun 01; 23(11):3200-3. PubMed ID: 23639537
    [Abstract] [Full Text] [Related]

  • 38. Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents.
    Xie R, Yao Y, Tang P, Chen G, Liu X, Yun F, Cheng C, Wu X, Yuan Q.
    Eur J Med Chem; 2017 Jul 07; 134():1-12. PubMed ID: 28391133
    [Abstract] [Full Text] [Related]

  • 39. Amide-based derivatives of β-alanine hydroxamic acid as histone deacetylase inhibitors: attenuation of potency through resonance effects.
    Liao V, Liu T, Codd R.
    Bioorg Med Chem Lett; 2012 Oct 01; 22(19):6200-4. PubMed ID: 22932316
    [Abstract] [Full Text] [Related]

  • 40. Design, synthesis and preliminary evaluation of a series of histone deacetylase inhibitors carrying a benzodiazepine ring.
    Guandalini L, Balliu M, Cellai C, Martino MV, Nebbioso A, Mercurio C, Carafa V, Bartolucci G, Dei S, Manetti D, Teodori E, Scapecchi S, Altucci L, Paoletti F, Romanelli MN.
    Eur J Med Chem; 2013 Aug 01; 66():56-68. PubMed ID: 23792316
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 26.